

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Tsav, Marsha M.

Group Art Unit: 1656

In re PATENT APPLICATION of

Applicants: HOSOKAWA ET AL.

Serial No. : 10/599,050

Filed : June 29, 2007

For : THROMBIN DERIVATIVES AND PHARMACEUTICAL)
COMPOSITION CONTAINING THE SAME)

AMENDMENT

No fee is believed to be due. However, the Commissioner is authorized to charge any fees required in connection with the filing of this paper to account No. 50-0710 (Order No.: JCLA21671)

RESPONSE TO RESTRICTION REQUIREMENT

MAIL STOP Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir,

In response to the Requirement of January 15, 2010, Applicants have elected Group I including claims 1-20, 37-48, 50-57 and elected a Species being blood coagulation factor 13 on which claims 1-4, 6-20, 37-39, 42-43, 45-48, 50 are readable, withdrawn the claims of the non-elected Groups and Species, and amended/canceled claims 1-2 & 10-11/6-7. Nevertheless, Applicants submit that two more Species should be elected from claims 40-41, 44 and claim 51-57 respectively as the modifications in claims 40-41, 44, the agents/ effects in claims 51-57 and the thrombin substrates in claims 4-5 are clearly in different categories, and would like to further elect carbodiimide from claims 40-41 & 44 and elect the antithrombotic agent from claim 51-57. Please enter the following amendments.